Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2017-04-28 AGM Information
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
Rendiconto sintetico votazioni Assemblea 27 aprile 2017
AGM Information Classification · 99% confidence The document is titled "ASSEMBLEA ORDINARIA DEGLI AZIONISTI" (Ordinary Shareholders' Meeting) and provides a "Rendiconto sintetico delle votazioni sui punti all'ordine del giorno dell'Assemblea" (Summary report of the votes on the agenda items of the Meeting). It details the voting results (Favorevoli, Contrarie, Astenute) for several resolutions, including approval of the financial statements, remuneration report, director appointment, stock option plan, and share buyback authorization. This content directly relates to the outcomes and proceedings of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2017-04-28 Italian
DiaSorin S.p.A.-Annual Financial Report 2016
Annual Report Classification · 100% confidence The document is titled 'ANNUAL FINANCIAL REPORT DECEMBER 31, 2016' and contains a comprehensive set of financial statements, including consolidated income statements, balance sheets, cash flow statements, notes to the financial statements, and independent auditors' reports. It covers the full fiscal year and provides detailed operational and financial performance analysis, which aligns perfectly with the definition of an Annual Report (10-K). FY 2016
2017-04-10 Italian
DiaSorin S.p.A.-Relazione Finanziaria Annuale Esercizio 2016
Annual Report Classification · 100% confidence The document is titled 'RELAZIONE FINANZIARIA ANNUALE AL 31 DICEMBRE 2016' (Annual Financial Report as of December 31, 2016). It contains a comprehensive set of financial statements, including the consolidated balance sheet, income statement, cash flow statement, and notes to the accounts for the full fiscal year. It also includes the management report (Relazione sulla gestione) and the audit report (Relazione della società di revisione). This matches the definition of an Annual Report (10-K). FY 2016
2017-04-06 Italian
DiaSorin S.p.A.-Compensation Report Reporting Year 2016
Remuneration Information Classification · 100% confidence The document is explicitly titled "COMPENSATION REPORT OF DIASORIN S.p.A Reporting year 2016" and repeatedly refers to the "Compensation Report" prepared pursuant to Article 123-ter of the Uniform Financial Code (TUF) and Consob regulations. This content directly addresses the remuneration policy, compensation of directors and executives, and related governance procedures. This aligns perfectly with the definition for Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors.
2017-04-05 Italian
DiaSorin S.p.A.-Relazione sulla remunerazione Esercizio 2016
Remuneration Information Classification · 99% confidence The document title is "RELAZIONE SULLA REMUNERAZIONE DELLA DIASORIN S.p.A. Esercizio 2016" (Remuneration Report of Diasorin S.p.A. Fiscal Year 2016). The text explicitly states it is prepared pursuant to Article 123-ter of the TUF (Testo Unico della Finanza) and Article 84-quater of the Issuers' Regulation. Article 123-ter of the Italian Consolidated Finance Act mandates the publication of a Remuneration Report detailing the policy and amounts paid to directors and management. This directly corresponds to the definition of Remuneration Information, which maps to the code DEF 14A (Proxy Solicitation & Information Statement, often used for proxy/governance disclosures like compensation reports in US context, but here, based on the specific content focusing entirely on compensation policy and amounts, DEF 14A is the closest fit among the provided options, as it relates to executive compensation disclosure, even if the source regulation is Italian). The content discusses the remuneration policy for directors and strategic executives, stock option plans, and the role of the Remuneration Committee. This is a detailed report, not just an announcement of a report.
2017-04-05 Italian
DiaSorin S.p.A.-Relazione Finanziaria Annuale Esercizio 2016
Annual Report Classification · 100% confidence The document is titled 'RELAZIONE FINANZIARIA ANNUALE AL 31 DICEMBRE 2016' (Annual Financial Report as of December 31, 2016) for DiaSorin S.p.A. It contains a comprehensive set of financial statements, including the consolidated balance sheet, income statement, cash flow statement, notes to the accounts, and the auditor's report. This structure corresponds to a full annual report (10-K equivalent in international reporting standards). FY 2016
2017-04-05 Italian

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.